Today: 21 March 2026
Subscribe
Browse Category

NASDAQ:LPTX 13 November 2025 - 10 December 2025

Cypherpunk Technologies (CYPH) Stock: Zcash Treasury Pivot, Winklevoss Backing and 2026 Forecast Explained

Cypherpunk Technologies (CYPH) Stock: Zcash Treasury Pivot, Winklevoss Backing and 2026 Forecast Explained

Cypherpunk Technologies Inc. (NASDAQ: CYPH), formerly Leap Therapeutics, closed at $1.62 on December 9, 2025, up nearly 40% after pivoting from biotech to a Zcash-focused treasury strategy backed by Winklevoss Capital. The stock has seen trading halts, insider sales, and sharp volatility since the rebrand and $58.88 million private placement in October.
10 December 2025
·····
Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

Leap Therapeutics rebranded as Cypherpunk Technologies Inc. and changed its Nasdaq ticker from LPTX to CYPH on November 13, 2025. The company raised $58.88 million in a private placement led by Winklevoss Capital and spent $50 million buying 203,775 Zcash. Shares surged up to 440% after the announcement, with LPTX trading near $2.05 and ZEC at $502 early Thursday. Q3 results show a sharply reduced net loss as biotech spending falls.
13 November 2025
···

Stock Market Today

  • UniFirst (UNF) Valuation At Odds With Strong 90-Day Stock Surge
    March 21, 2026, 12:02 AM EDT. UniFirst (UNF) shares closed at $260.76 after a robust 53.24% gain over 90 days, drawing investor attention to its $2.45 billion revenue and $139.53 million net income from uniform and safety services. Despite a recent 1.79% daily dip, UniFirst's 1-year shareholder return stands at 33.18%. The stock trades near analyst targets but appears 12% overvalued against a fair value estimate of $232, reflecting a 6.98% discount rate. Analysts' consensus price target is $178.25, with forecasts varying from $152 to $194, signaling mixed views on growth and margins. Risks include declining usage levels and rising healthcare costs, potentially affecting revenue and margins. Investors are advised to assess these dynamics and broader market options before making decisions.
Go toTop